No Difference in Anti-VEGF Drugs for Wet AMD
(MedPage Today) -- Researchers conducting a closely watched head-to-head study of intravitreal bevacizumab (Avastin) and ranibizumab (Lucentis) for slowing "wet" age-related macular degeneration (AMD) will report that the drugs were equally effective, according to the New York Times.